L-proline derivative - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	L-proline derivative	go back to main search page
Accession:	CHEBI:84186	browse the term
Definition:	A proteinogenic amino acid derivative resulting from reaction of L-proline at the amino group or the carboxy group, or from the replacement of any hydrogen of L-proline by a heteroatom.
Synonyms:	related_synonym:	L-proline derivatives

show annotations for term's descendants Sort by:
Rat (274) Mouse (277) Human (275) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (274)

5-oxo-L-proline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

DEK proto-oncogene

multiple interactions

DEK protein results in decreased chemical synthesis of and results in increased uptake of Pyrrolidonecarboxylic Acid

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

insulin 2

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

captopril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions
decreases activity

Captopril inhibits the reaction [Pregabalin results in increased expression of ACE protein]
Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE protein]
Captopril results in decreased activity of ACE protein

PMID:26851370 PMID:31629013 PMID:33007385

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

decreases response to substance
multiple interactions

ACE2 gene SNP results in decreased susceptibility to Captopril
Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]
Captopril inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein]

PMID:17473847 PMID:31629013 PMID:33007385

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]

PMID:31181250 PMID:33007385

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

angiotensinogen

multiple interactions

[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of AGT protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of AGT protein]; Captopril inhibits the reaction [Pregabalin results in decreased expression of AGT protein]
Captopril inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGT protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Cadmium Chloride results in increased expression of AGT protein]

PMID:28130181 PMID:31181250 PMID:31629013 PMID:33007385 PMID:35844137 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

multiple interactions

Captopril inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein]
Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein]

PMID:28130181 PMID:31629013 PMID:33007385

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

AKT serine/threonine kinase 1

multiple interactions

Captopril inhibits the reaction [Glucose results in increased expression of AKT1 mRNA]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

alkaline phosphatase, biomineralization associated

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of ALPL protein]

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

bradykinin receptor B2

multiple interactions

Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein]

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

calbindin 1

multiple interactions

Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein]

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

carbonic anhydrase 2

multiple interactions

Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA]

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

caspase 3

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]
Captopril inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]

PMID:27269004 PMID:38115276

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cadherin 1

multiple interactions

Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type III alpha 1 chain

multiple interactions

Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

GLI family zinc finger 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 2

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

GLI family zinc finger 3

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

glutamic-oxaloacetic transaminase 1

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 6

multiple interactions

[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of IL6 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of IL6 protein]
Captopril inhibits the reaction [Glucose results in increased expression of IL6 mRNA]

PMID:38027817 PMID:38115276

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

kininogen 1

multiple interactions

[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of KNG1 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of KNG1 protein]

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

leptin receptor

multiple interactions
affects response to substance

Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein]; Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein]; Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of VDR protein]
LEPR protein affects the susceptibility to Captopril

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

Captopril inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein]
Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein]

PMID:31629013 PMID:33007385

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

microRNA 146a

multiple interactions

captopril inhibits the reaction [ischemia-reperfusion injury increases expression of Mir146a miRNA in kidney]

RGD

NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610

G

microRNA 320a

multiple interactions

captopril inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in kidney]

RGD

NCBI chr15:45,516,392...45,516,473
Ensembl chr15:45,516,392...45,516,473

G

mixed lineage kinase domain like pseudokinase

multiple interactions

Captopril inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MLKL protein]

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

matrix metallopeptidase 9

multiple interactions

Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nitric oxide synthase 2

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide B

multiple interactions

Captopril inhibits the reaction [Pregabalin results in increased expression of NPPB protein]

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

Captopril inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

patched 1

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]

NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Captopril inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein]
Captopril inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]

PMID:27269004 PMID:38115276

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parathyroid hormone

multiple interactions

Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein]

NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Captopril inhibits the reaction [Glucose results in increased phosphorylation of and results in increased localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

receptor-interacting serine-threonine kinase 3

multiple interactions

Captopril inhibits the reaction [Cadmium Chloride results in increased expression of RIPK3 protein]

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

RUNX family transcription factor 2

multiple interactions

Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

sonic hedgehog signaling molecule

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

smoothened, frizzled class receptor

multiple interactions

[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]

NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829

G

superoxide dismutase 1

multiple interactions

Captopril inhibits the reaction [Methotrexate results in decreased expression of and results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

transforming growth factor, beta 1

multiple interactions

[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TNF protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of TNF protein]
Captopril inhibits the reaction [Glucose results in increased expression of TNF mRNA]

PMID:38027817 PMID:38115276

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

Captopril inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vitamin D receptor

multiple interactions

Captopril promotes the reaction [LEPR protein affects the expression of VDR protein]

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions

Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions

Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

clindamycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

Clindamycin results in increased expression of and results in increased activity of CYP3A4 protein
Clindamycin results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

matrix metallopeptidase 13

increases expression

Clindamycin results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

RT1 class Ia, locus A2

affects expression

Clindamycin affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class II, locus Db1

affects expression

Clindamycin affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

clindamycin phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

paraoxonase 1

decreases activity

clindamycin phosphate results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

domoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression
increases localization
multiple interactions

domoic acid results in increased expression of BAX mRNA
domoic acid results in increased localization of BAX protein
Carbachol inhibits the reaction [domoic acid results in increased localization of BAX protein]

PMID:18293405 PMID:19200344

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects expression

domoic acid affects the expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

Carbachol inhibits the reaction [domoic acid results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

glutamate-cysteine ligase, catalytic subunit

increases expression

domoic acid results in increased expression of GCLC mRNA; domoic acid results in increased expression of GCLC protein

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
decreases response to substance
affects response to substance

domoic acid results in increased expression of GCLM mRNA; domoic acid results in increased expression of GCLM protein
[GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to 2,3-dimethoxy-1,4-naphthoquinone; [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to Hydrogen Peroxide; GCLM protein results in decreased susceptibility to domoic acid; GCLM results in decreased susceptibility to domoic acid
GCLM affects the susceptibility to domoic acid

PMID:17804861 PMID:19200344 PMID:23315585

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutamate ionotropic receptor AMPA type subunit 1

increases phosphorylation

domoic acid results in increased phosphorylation of GRIA1 protein

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

parvalbumin

increases expression

domoic acid results in increased expression of PVALB protein

NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561

G

WD repeat domain 35

increases expression
multiple interactions

domoic acid results in increased expression of WDR35 mRNA; domoic acid results in increased expression of WDR35 protein
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [domoic acid results in increased expression of WDR35 protein]; Edaravone inhibits the reaction [domoic acid results in increased expression of WDR35 protein]

NCBI chr 6:31,771,315...31,831,450
Ensembl chr 6:31,771,360...31,831,029

fosinopril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

decreases response to substance

ABCC1 protein results in decreased susceptibility to Fosinopril

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

decreases response to substance
increases export
multiple interactions

ABCC2 protein results in decreased susceptibility to Fosinopril
ABCC2 protein results in increased export of Fosinopril
desloratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Loratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Methotrexate inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]
ABCC2 protein affects the reaction [Fosinopril affects the export of Methotrexate]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

adiponectin receptor 2

increases expression

fosinopril increases expression of adipor2 mRNA in rat liver

RGD

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

alpha-fetoprotein

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein]

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

angiotensinogen

decreases expression

Fosinopril results in decreased expression of AGT protein

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

bone morphogenetic protein receptor type 2

multiple interactions

Fosinopril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BMPR2 mRNA]

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

cyclin D1

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

glutamic--pyruvic transaminase

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

Klotho

increases expression

Fosinopril results in increased expression of KL mRNA; Fosinopril results in increased expression of KL protein

NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080

G

matrix metallopeptidase 2

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

decreases expression
multiple interactions

Fosinopril results in decreased expression of MMP9 mRNA; Fosinopril results in decreased expression of MMP9 protein
[Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear factor kappa B subunit 1

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 3

affects expression

Fosinopril affects the expression of NOS3 mRNA; Fosinopril affects the expression of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

phosphodiesterase 1A

affects expression

Fosinopril affects the expression of PDE1A mRNA; Fosinopril affects the expression of PDE1A protein

NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874

G

phosphodiesterase 1C

affects expression

Fosinopril affects the expression of PDE1C mRNA; Fosinopril affects the expression of PDE1C protein

NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

serpin family E member 1

decreases expression
multiple interactions

Fosinopril results in decreased expression of SERPINE1 mRNA; Fosinopril results in decreased expression of SERPINE1 protein
[Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 protein

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 15 member 1

multiple interactions

Fosinopril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 15 member 2

multiple interactions

Fosinopril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225

G

transforming growth factor, beta 1

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

decreases expression
multiple interactions

Fosinopril results in decreased expression of TIMP1 mRNA; Fosinopril results in decreased expression of TIMP1 protein
[Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 protein

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions

Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

kainic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression

Kainic Acid results in increased expression of ABCB1A mRNA; Kainic Acid results in increased expression of ABCB1A protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases expression

Kainic Acid results in increased expression of ABCB1B mRNA; Kainic Acid results in increased expression of ABCB1B protein

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily G member 2

increases expression

Kainic Acid results in increased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

aconitase 2

multiple interactions
decreases activity

6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein]

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acid phosphatase 1

decreases expression

Kainic Acid results in decreased expression of ACP1 mRNA

NCBI chr 6:47,506,380...47,522,021
Ensembl chr 6:47,506,380...47,522,021

G

adenosine kinase

increases expression

Kainic Acid results in increased expression of ADK mRNA

NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510

G

activity-dependent neuroprotector homeobox

multiple interactions
decreases expression

Enzyme Inhibitors inhibits the reaction [Kainic Acid results in decreased expression of ADNP protein]
Kainic Acid results in decreased expression of ADNP mRNA; Kainic Acid results in decreased expression of ADNP protein

NCBI chr 3:156,886,921...156,921,500
Ensembl chr 3:156,891,381...156,917,312

G

adrenoceptor alpha 1B

increases response to substance

ADRA1B protein results in increased susceptibility to Kainic Acid

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

allograft inflammatory factor 1

increases expression
multiple interactions

Kainic Acid results in increased expression of AIF1 protein
[cyanoginosin LR co-treated with Kainic Acid] results in increased expression of AIF1 protein
NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein]

PMID:32057834 PMID:34352349

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

apoptosis inducing factor, mitochondria associated 1

increases localization
multiple interactions

Kainic Acid results in increased localization of AIFM1 protein
Minocycline inhibits the reaction [Kainic Acid results in increased localization of AIFM1 protein]

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

arachidonate 5-lipoxygenase activating protein

increases expression

Kainic Acid results in increased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

apoptotic peptidase activating factor 1

increases expression

Kainic Acid results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

apurinic/apyrimidinic endodeoxyribonuclease 1

multiple interactions

[Raloxifene Hydrochloride co-treated with Kainic Acid] results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

apolipoprotein E

decreases expression

Kainic Acid results in decreased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

activity-regulated cytoskeleton-associated protein

increases expression

Kainic Acid results in increased expression of ARC mRNA; Kainic Acid results in increased expression of ARC protein

PMID:17632064 PMID:30557575

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

activating transcription factor 7 interacting protein

decreases expression

Kainic Acid results in decreased expression of ATF7IP mRNA

NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650

G

autophagy related 5

multiple interactions
increases expression

NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

beta-1,4-galactosyltransferase 2

decreases expression

Kainic Acid results in decreased expression of B4GALT2 mRNA

NCBI chr 5:131,412,541...131,422,573
Ensembl chr 5:131,412,541...131,421,013

G

BAG cochaperone 3

increases expression

Kainic Acid results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Kainic Acid results in increased expression of BAX mRNA; Kainic Acid results in increased expression of BAX protein
oridonin inhibits the reaction [Kainic Acid results in increased expression of BAX mRNA]
EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]]
Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of BAX protein]

PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]
Kainic Acid results in decreased expression of BCL2 mRNA
oridonin inhibits the reaction [Kainic Acid results in decreased expression of BCL2 mRNA]

PMID:25453207 PMID:31430510

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions
increases expression

[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]
Kainic Acid results in increased expression of BDNF mRNA; Kainic Acid results in increased expression of BDNF protein

PMID:1641125 PMID:9073163 PMID:11279263 PMID:16166269 PMID:17827730 More...

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

multiple interactions
increases expression

NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

complement C1q B chain

increases expression

Kainic Acid results in increased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C4B

increases expression

Kainic Acid results in increased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

calbindin 1

decreases expression

Kainic Acid results in decreased expression of CALB1 mRNA

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions
increases phosphorylation

cyanoginosin LR inhibits the reaction [Kainic Acid results in increased phosphorylation of CAMK2A protein]

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

Kainic Acid results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calpain, small subunit 1

increases expression

Kainic Acid results in increased expression of CAPNS1 mRNA

NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795

G

caspase 3

increases activity
increases expression
multiple interactions
increases cleavage

Kainic Acid results in increased activity of CASP3 protein
Kainic Acid results in increased expression of CASP3 protein
oridonin inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein]
EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein]
Kainic Acid results in increased cleavage of CASP3 protein
Kainic Acid results in increased expression of CASP3 mRNA; Kainic Acid results in increased expression of CASP3 protein
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein]; Minocycline inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]

PMID:16469440 PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases expression
multiple interactions
decreases activity

Kainic Acid results in decreased expression of CAT mRNA; Kainic Acid results in decreased expression of CAT protein
Diazepam inhibits the reaction [Kainic Acid results in decreased activity of CAT protein]
oridonin inhibits the reaction [Kainic Acid results in decreased activity of CAT protein]

PMID:29208536 PMID:31430510 PMID:35544363

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

decreases expression

Kainic Acid results in decreased expression of CCK protein

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 2

increases expression

Kainic Acid results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin E1

increases expression

Kainic Acid results in increased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

Cd68 molecule

increases expression

Kainic Acid results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

cell division cycle 42

increases expression

Kainic Acid results in increased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cadherin 13

increases expression

Kainic Acid results in increased expression of CDH13 mRNA

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cyclin dependent kinase 2

increases expression

Kainic Acid results in increased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

CEA cell adhesion molecule 1

increases expression

Kainic Acid results in increased expression of CEACAM1 mRNA

NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992

G

chromogranin B

increases expression

Kainic Acid results in increased expression of CHGB mRNA

NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

increases expression

Kainic Acid results in increased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cannabinoid receptor 1

increases expression

Kainic Acid results in increased expression of CNR1 mRNA

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor interacting protein 1

increases expression

Kainic Acid results in increased expression of CNRIP1 mRNA

NCBI chr14:91,462,877...91,492,739
Ensembl chr14:91,462,647...91,492,735

G

collagen type I alpha 1 chain

increases expression

Kainic Acid results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

corticotropin releasing hormone receptor 1

increases expression

Kainic Acid results in increased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

cathepsin B

multiple interactions
increases expression

NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions
increases expression

NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin S

increases expression

Kainic Acid results in increased expression of CTSS mRNA; Kainic Acid results in increased expression of CTSS protein

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cathepsin Z

increases expression

Kainic Acid results in increased expression of CTSZ mRNA

NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645

G

cytochrome c, somatic

increases localization
multiple interactions
increases expression

Kainic Acid results in increased localization of CYCS protein
Minocycline inhibits the reaction [Kainic Acid results in increased localization of CYCS protein]
Kainic Acid results in increased expression of CYCS mRNA

PMID:16469440 PMID:19700661

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

DiGeorge syndrome critical region gene 6

decreases expression

Kainic Acid results in decreased expression of DGCR6 mRNA

NCBI chr11:82,927,725...82,932,823
Ensembl chr11:82,927,725...82,932,823

G

DEAH-box helicase 36

increases expression

Kainic Acid results in increased expression of DHX36 mRNA

NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572

G

diablo, IAP-binding mitochondrial protein

increases expression

Kainic Acid results in increased expression of DIABLO mRNA

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

dopamine receptor D2

decreases response to substance

DRD2 protein results in decreased susceptibility to Kainic Acid

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

early growth response 1

decreases expression
affects expression

Kainic Acid results in decreased expression of EGR1 mRNA
Kainic Acid affects the expression of EGR1 mRNA

PMID:17997037 PMID:19700661

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[cyanoginosin LR co-treated with Kainic Acid] results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

kainic acid increases phosphorylation of Eif2s1 in rat neurons

RGD

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 4A3

increases expression

Kainic Acid results in increased expression of EIF4A3 protein

NCBI chr10:104,549,038...104,559,032
Ensembl chr10:104,549,038...104,559,057

G

ER membrane protein complex subunit 3

decreases expression

Kainic Acid results in decreased expression of EMC3 mRNA

NCBI chr 4:146,663,065...146,678,976
Ensembl chr 4:146,663,067...146,679,029

G

engrailed homeobox 2

affects response to substance
decreases expression

EN2 protein affects the susceptibility to Kainic Acid
Kainic Acid results in decreased expression of EN2 mRNA

NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943

G

ectodermal-neural cortex 1

decreases expression

Kainic Acid results in decreased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

erythropoietin

multiple interactions

EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]]

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

multiple interactions
decreases expression

EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]]

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

electron transfer flavoprotein subunit beta

decreases expression

Kainic Acid results in decreased expression of ETFB mRNA

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

F-box and WD repeat domain containing 5

decreases expression

Kainic Acid results in decreased expression of FBXW5 mRNA

NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092

G

fibroblast growth factor 2

increases expression

Kainic Acid results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 5

increases expression

Kainic Acid results in increased expression of FGF5 mRNA

NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997

G

Fibroblast growth factor receptor 1

increases expression

Kainic Acid results in increased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases expression

10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone inhibits the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; [Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein]
Kainic Acid results in increased expression of FOS mRNA; Kainic Acid results in increased expression of FOS protein
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [Phenytoin co-treated with Drugs, Chinese Herbal] inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein]
Kainic Acid results in decreased expression of FOS mRNA

PMID:7655348 PMID:7887109 PMID:8417141 PMID:8758711 PMID:15723099 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 2, AP-1 transcription factor subunit

increases expression

Kainic Acid results in increased expression of FOSL2 mRNA

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

FXYD domain-containing ion transport regulator 1

decreases expression

Kainic Acid results in decreased expression of FXYD1 mRNA

NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278

G

gamma-aminobutyric acid type A receptor subunit beta1

increases expression
multiple interactions

Kainic Acid results in increased expression of GABRB1 mRNA
Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB1 mRNA]

NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948

G

gamma-aminobutyric acid type A receptor subunit beta 3

multiple interactions
increases expression

Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB3 mRNA]

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961

G

glutamate decarboxylase 1

increases expression

Kainic Acid results in increased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

increases expression

Kainic Acid results in increased expression of GAD2 mRNA

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Kainic Acid results in increased expression of GADD45A mRNA; Kainic Acid results in increased expression of GADD45A protein

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

decreases expression

Kainic Acid results in decreased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

decreases expression

Kainic Acid results in decreased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

growth associated protein 43

multiple interactions
increases expression

Dizocilpine Maleate inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA]

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

glucosaminyl (N-acetyl) transferase 2

increases expression

Kainic Acid results in increased expression of GCNT2 mRNA

NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611

G

glial fibrillary acidic protein

increases expression
multiple interactions

Kainic Acid results in increased expression of GFAP mRNA; Kainic Acid results in increased expression of GFAP protein
NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]
EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]
PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA]

PMID:17997037 PMID:18711747 PMID:19700661 PMID:21589914 PMID:22790971 More...

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutamate-ammonia ligase

multiple interactions
decreases expression

oridonin inhibits the reaction [Kainic Acid results in decreased expression of GLUL mRNA]

NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108

G

glutathione peroxidase 1

decreases expression

Kainic Acid results in decreased expression of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions
increases phosphorylation
decreases expression

2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of GRIA1 protein]; Kainic Acid binds to and results in increased activity of GRIA1 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA1 protein]
Kainic Acid results in increased phosphorylation of GRIA1 protein
Kainic Acid results in decreased expression of GRIA1 mRNA
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; Kainic Acid inhibits the reaction [cyanoginosin LR results in increased expression of and results in increased phosphorylation of GRIA1 protein]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]
Kainic Acid results in decreased expression of GRIA1 mRNA; Kainic Acid results in decreased expression of GRIA1 protein

PMID:7529610 PMID:11812690 PMID:17585341 PMID:21589914 PMID:34352349

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions
increases methylation
decreases expression
affects response to substance

Kainic Acid binds to and results in increased activity of GRIA2 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein]
Kainic Acid results in increased methylation of GRIA2 gene
Kainic Acid results in decreased expression of GRIA2 mRNA
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA]; RG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene]
GRIA2 protein affects the susceptibility to Kainic Acid

PMID:7529610 PMID:10551584 PMID:11812690 PMID:21589914 PMID:24098468

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression
multiple interactions
increases expression

Kainic Acid results in decreased expression of GRIA3 mRNA
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA3 mRNA]
Kainic Acid results in increased expression of GRIA3 mRNA

PMID:7529610 PMID:21589914

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

G

glutamate ionotropic receptor AMPA type subunit 4

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIA4 mRNA
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA4 mRNA]

NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979

G

glutamate ionotropic receptor kainate type subunit 1

decreases expression
increases expression
multiple interactions

Kainic Acid results in decreased expression of GRIK1 mRNA
Kainic Acid results in increased expression of GRIK1 mRNA
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]

PMID:21589914 PMID:29208536

NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645

G

glutamate ionotropic receptor kainate type subunit 2

increases expression
multiple interactions

Kainic Acid results in increased expression of GRIK2 mRNA
[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK2 mRNA

PMID:17997037 PMID:21589914 PMID:29208536

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIK3 mRNA
[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK3 mRNA

NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307

G

glutamate ionotropic receptor kainate type subunit 4

multiple interactions
decreases expression

[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK4 mRNA; Kainic Acid promotes the reaction [cyanoginosin LR affects the localization of GRIK4 protein]
Kainic Acid results in decreased expression of GRIK4 mRNA

PMID:21589914 PMID:34352349

NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751

G

glutamate ionotropic receptor kainate type subunit 5

multiple interactions
decreases expression

Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]

NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions
affects expression
decreases expression

celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN1 mRNA]
Kainic Acid affects the expression of GRIN1

PMID:21589914 PMID:23159308

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIN2A mRNA
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2A mRNA]

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions
decreases expression

celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2B mRNA]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glutamate ionotropic receptor NMDA type subunit 2C

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIN2C mRNA
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]

NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427

G

glutamate ionotropic receptor NMDA type subunit 2D

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIN2D mRNA
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]

NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793

G

glutamate ionotropic receptor NMDA type subunit 3A

multiple interactions
decreases expression

Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]

NCBI chr 5:64,006,847...64,206,408
Ensembl chr 5:64,009,980...64,206,085

G

glutamate ionotropic receptor NMDA type subunit 3B

decreases expression
multiple interactions

Kainic Acid results in decreased expression of GRIN3B mRNA
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3B mRNA]

NCBI chr 7:9,730,861...9,737,183
Ensembl chr 7:9,730,862...9,737,183

G

glycogen synthase kinase 3 beta

decreases activity
decreases phosphorylation
multiple interactions

Kainic Acid results in decreased activity of GSK3B protein
Kainic Acid results in decreased phosphorylation of GSK3B protein
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]

PMID:18619545 PMID:25453207

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions
decreases activity

oridonin inhibits the reaction [Kainic Acid results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hyperpolarization-activated cyclic nucleotide-gated potassium channel 1

multiple interactions
decreases expression

Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein]
Kainic Acid results in decreased expression of HCN1 mRNA; Kainic Acid results in decreased expression of HCN1 protein

NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774

G

high mobility group box 1

multiple interactions
increases expression

Kainic Acid results in increased expression of and affects the localization of HMGB1 protein; perampanel inhibits the reaction [Kainic Acid results in increased expression of and affects the localization of HMGB1 protein]
Kainic Acid results in increased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

increases expression

Kainic Acid results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

increases expression

Kainic Acid results in increased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

hippocalcin

decreases response to substance

HPCA protein results in decreased susceptibility to Kainic Acid

NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841

G

hydroxysteroid 11-beta dehydrogenase 1

decreases expression

Kainic Acid results in decreased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein]; GYKI 52466 inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein]

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Kainic Acid results in decreased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interleukin 10

decreases expression

Kainic Acid results in decreased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12A

affects response to substance

IL12A protein affects the susceptibility to Kainic Acid

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 1 beta

increases secretion
increases expression
multiple interactions

Kainic Acid results in increased secretion of IL1B protein
Kainic Acid results in increased expression of IL1B mRNA; Kainic Acid results in increased expression of IL1B protein
Diazepam inhibits the reaction [Kainic Acid results in increased expression of IL1B protein]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA]
Minocycline inhibits the reaction [Kainic Acid results in increased secretion of IL1B protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL1B protein]; perampanel inhibits the reaction [Kainic Acid results in increased expression of IL1B protein]

PMID:7655348 PMID:11306611 PMID:21589914 PMID:31430510 PMID:35544363 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases response to substance
multiple interactions
increases expression

IL6 protein results in increased susceptibility to Kainic Acid
oridonin inhibits the reaction [Kainic Acid results in increased expression of IL6 protein]
Kainic Acid results in increased expression of IL6 mRNA
PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA]

PMID:12836160 PMID:21589914 PMID:31430510

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

increases expression
multiple interactions

Kainic Acid results in increased expression of ITGAM mRNA
PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

jagunal homolog 1

decreases expression

Kainic Acid results in decreased expression of JAGN1 mRNA

NCBI chr 4:146,591,577...146,596,287
Ensembl chr 4:146,591,510...146,596,288

G

Janus kinase 2

multiple interactions
decreases expression

EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of JUN protein]
Kainic Acid results in increased expression of JUN mRNA; Kainic Acid results in increased expression of JUN protein

PMID:8417141 PMID:15723099 PMID:17827730

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression

Kainic Acid results in decreased expression of JUNB mRNA
Kainic Acid results in increased expression of JUNB mRNA

PMID:17997037 PMID:19700661

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

kalirin, RhoGEF kinase

increases expression

Kainic Acid results in increased expression of KALRN mRNA

NCBI chr11:66,198,155...66,803,166
Ensembl chr11:66,198,173...66,797,610

G

potassium voltage-gated channel subfamily C member 2

increases expression

Kainic Acid results in increased expression of KCNC2 protein

NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968

G

potassium voltage-gated channel subfamily C member 4

decreases expression

Kainic Acid results in decreased expression of KCNC4 protein

NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233

G

potassium voltage-gated channel subfamily Q member 2

increases response to substance

KCNQ2 protein mutant form results in increased susceptibility to Kainic Acid

NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071

G

kinesin family member 20A

decreases expression

Kainic Acid results in decreased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

KLF transcription factor 10

decreases expression

Kainic Acid results in decreased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

kininogen 1

multiple interactions

Kainic Acid promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form]

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

KRAS proto-oncogene, GTPase

increases expression

Kainic Acid results in increased expression of KRAS mRNA

NCBI chr 4:178,185,418...178,218,484

G

leptin

decreases response to substance

LEP protein results in decreased susceptibility to Kainic Acid

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

LIM domain only 1

decreases expression

Kainic Acid results in decreased expression of LMO1 mRNA

NCBI chr 1:163,132,338...163,168,521
Ensembl chr 1:163,132,339...163,168,522

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

microtubule-associated protein 2

multiple interactions
increases expression

PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen-activated protein kinase kinase kinase 5

decreases expression

Kainic Acid results in decreased expression of MAP3K5 mRNA

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

Kainic Acid results in increased phosphorylation of MAPK1 protein
cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases expression
increases phosphorylation
multiple interactions

Kainic Acid results in increased expression of MAPK3 mRNA
Kainic Acid results in increased phosphorylation of MAPK3 protein
cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK3 protein]

PMID:17997037 PMID:34352349

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule associated serine/threonine kinase 3

decreases expression

Kainic Acid results in decreased expression of MAST3 mRNA

NCBI chr16:18,636,764...18,663,852
Ensembl chr16:18,636,787...18,663,852

G

matrix metallopeptidase 9

increases activity
multiple interactions

Kainic Acid results in increased activity of MMP9 protein
MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

multiple PDZ domain crumbs cell polarity complex component

affects response to substance

MPDZ protein affects the susceptibility to Kainic Acid

NCBI chr 5:95,766,112...95,920,531
Ensembl chr 5:95,766,118...95,920,499

G

macrophage expressed 1

increases expression

Kainic Acid results in increased expression of MPEG1 mRNA

NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855

G

methylsterol monooxygenase 1

decreases expression

Kainic Acid results in decreased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

metallothionein 1

increases expression

Kainic Acid results in increased expression of MT1A mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

decreases response to substance

MT2 protein results in decreased susceptibility to Kainic Acid

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

myosin Vb

decreases expression

Kainic Acid results in decreased expression of MYO5B mRNA

NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745

G

myosin IXA

increases expression

Kainic Acid results in increased expression of MYO9A mRNA

NCBI chr 8:60,149,234...60,352,330
Ensembl chr 8:60,149,234...60,350,514

G

NLR family, apoptosis inhibitory protein 6

increases expression

Kainic Acid results in increased expression of NAIP mRNA; Kainic Acid results in increased expression of NAIP protein

PMID:12547647 PMID:15046874

NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542

G

neural cell adhesion molecule 1

decreases expression
multiple interactions

Kainic Acid results in decreased expression of NCAM1 mRNA
MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form]

PMID:19700661 PMID:30772382

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

neurofilament light chain

increases secretion

Kainic Acid results in increased secretion of NEFL protein

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

NFE2 like bZIP transcription factor 2

affects localization

Kainic Acid affects the localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 1

multiple interactions
increases expression
decreases expression

2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of NOS1 protein]
Kainic Acid results in increased expression of NOS1 mRNA; Kainic Acid results in increased expression of NOS1 protein

PMID:17585341 PMID:18375135

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

increases expression
multiple interactions

Kainic Acid results in increased expression of NOS2 mRNA
Kainic Acid results in increased expression of NOS2 mRNA; Kainic Acid results in increased expression of NOS2 protein
PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA]
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; Curcumin inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]

PMID:17827730 PMID:18375135 PMID:21589914

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuropeptide Y

decreases response to substance
multiple interactions
increases expression

NPY protein results in decreased susceptibility to Kainic Acid
Thiopental inhibits the reaction [Kainic Acid results in increased expression of NPY mRNA]

PMID:9427505 PMID:15451008

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 4, group A, member 1

decreases expression
increases expression

Kainic Acid results in decreased expression of NR4A1 mRNA
Kainic Acid results in increased expression of NR4A1 mRNA

PMID:17997037 PMID:19700661

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Kainic Acid results in increased expression of NR4A2 mRNA
Kainic Acid results in increased expression of NR4A2 protein

PMID:19700661 PMID:24813937

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nuclear receptor subfamily 4, group A, member 3

increases expression

Kainic Acid results in increased expression of NR4A3 mRNA

NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733

G

neuropilin 2

affects response to substance

NRP2 protein affects the susceptibility to Kainic Acid

NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958

G

netrin 1

increases expression

Kainic Acid results in increased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

neurotrophic receptor tyrosine kinase 2

increases expression

Kainic Acid results in increased expression of NTRK2 mRNA

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

NudC domain containing 2

increases expression

Kainic Acid results in increased expression of NUDCD2 mRNA

NCBI chr10:25,163,247...25,168,738
Ensembl chr10:25,163,220...25,168,738

G

nudix hydrolase 4

increases expression

Kainic Acid results in increased expression of NUDT4 mRNA

NCBI chr 7:30,188,100...30,204,615
Ensembl chr 7:30,188,100...30,204,615

G

orthodenticle homeobox 2

decreases expression

Kainic Acid results in decreased expression of OTX2 mRNA

NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416

G

p21 (RAC1) activated kinase 3

decreases expression

Kainic Acid results in decreased expression of PAK3 mRNA

NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314

G

poly (ADP-ribose) polymerase 1

increases activity

Kainic Acid results in increased activity of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prodynorphin

multiple interactions
increases expression

Diazepam inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

proenkephalin

multiple interactions
increases expression

Diazepam inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Thiopental inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]

PMID:8417141 PMID:9427505

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

protein interacting with PRKCA 1

decreases expression

Kainic Acid results in decreased expression of PICK1 mRNA

NCBI chr 7:110,796,623...110,816,850
Ensembl chr 7:110,797,117...110,816,848

G

plakophilin 2

decreases expression

Kainic Acid results in decreased expression of PKP2 mRNA

NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

decreases expression

Kainic Acid results in decreased expression of PLOD3 mRNA

NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960

G

peptidylprolyl isomerase F

increases response to substance

PPIF results in increased susceptibility to Kainic Acid

NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913

G

protein phosphatase 1, regulatory subunit 9B

increases expression

Kainic Acid results in increased expression of PPP1R9B protein

NCBI chr10:79,938,055...79,954,085
Ensembl chr10:79,938,066...79,954,083

G

protein kinase C, delta

multiple interactions

[cyanoginosin LR co-treated with Kainic Acid] results in increased phosphorylation of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases response to substance
increases expression

[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; oridonin inhibits the reaction [Kainic Acid results in increased expression of PTGS2 protein]
[PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprost; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprostone; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Thromboxane B2; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA]
Kainic Acid results in increased expression of PTGS2; Kainic Acid results in increased expression of PTGS2 mRNA; Kainic Acid results in increased expression of PTGS2 protein

PMID:11168565 PMID:12618123 PMID:17827730 PMID:18834901 PMID:19700661 More...

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

QKI, KH domain containing RNA binding

increases expression

Kainic Acid results in increased expression of QKI mRNA

NCBI chr 1:50,387,716...50,501,568
Ensembl chr 1:50,387,698...50,498,831

G

Rac family small GTPase 1

increases expression

Kainic Acid results in increased expression of RAC1 mRNA

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

RAD23 homolog A, nucleotide excision repair protein

increases expression

Kainic Acid results in increased expression of RAD23A mRNA

NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695

G

ras related dexamethasone induced 1

decreases expression

Kainic Acid results in decreased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

RNA binding fox-1 homolog 1

increases response to substance

RBFOX1 gene mutant form results in increased susceptibility to Kainic Acid

NCBI chr10:8,152,198...10,248,120
Ensembl chr10:8,152,198...9,686,659

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression

PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RE1-silencing transcription factor

increases expression
multiple interactions

Kainic Acid results in increased expression of REST protein
Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein]

NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354

G

regulator of G-protein signaling 16

decreases expression

Kainic Acid results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

ras homolog family member A

increases expression

Kainic Acid results in increased expression of RHOA mRNA

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

sphingosine-1-phosphate receptor 1

decreases expression

Kainic Acid results in decreased expression of S1PR1 mRNA

NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681

G

SAP30-like

decreases expression

Kainic Acid results in decreased expression of SAP30L mRNA

NCBI chr10:41,979,730...41,992,307
Ensembl chr10:41,979,687...41,987,658

G

semaphorin 4D

increases expression

Kainic Acid results in increased expression of SEMA4D mRNA

NCBI chr17:13,430,324...13,537,146
Ensembl chr17:13,430,379...13,537,138

G

serpin family E member 1

multiple interactions
increases expression

Guanethidine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Mecamylamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Phentolamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

splicing factor proline and glutamine rich

increases expression

Kainic Acid results in increased expression of SFPQ mRNA

NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472

G

sigma non-opioid intracellular receptor 1

multiple interactions

SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]

NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017

G

sirtuin 1

decreases expression
increases expression

Kainic Acid results in decreased expression of SIRT1 protein
Kainic Acid results in increased expression of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 11 member 2

increases expression

Kainic Acid results in increased expression of SLC11A2

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

solute carrier family 1 member 1

decreases expression

Kainic Acid results in decreased expression of SLC1A1 mRNA

NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402

G

solute carrier family 1 member 2

multiple interactions
increases expression

[Kainic Acid co-treated with zinc chloride] results in decreased expression of SLC1A2 protein
Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein]

PMID:19061913 PMID:28257918

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 22 member 2

multiple interactions

Kainic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 6 member 2

increases response to substance

SLC6A2 protein results in increased susceptibility to Kainic Acid

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 8 member A3

multiple interactions
increases expression
increases cleavage

2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in increased cleavage of SLC8A3 protein]
Kainic Acid results in increased expression of SLC8A3 protein

PMID:17585341 PMID:20928830

NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508

G

SNF related kinase

decreases expression

Kainic Acid results in decreased expression of SNRK mRNA

NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323

G

superoxide dismutase 1

decreases expression

Kainic Acid results in decreased expression of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

decreases expression
increases expression

Kainic Acid results in decreased expression of SOD2 protein
Kainic Acid results in decreased expression of SOD2 mRNA; Kainic Acid results in decreased expression of SOD2 protein
Kainic Acid results in increased expression of SOD2 protein

PMID:10686417 PMID:29208536

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

spectrin, alpha, non-erythrocytic 1

increases expression

Kainic Acid results in increased expression of SPTAN1 protein modified form

NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046

G

sequestosome 1

decreases expression
multiple interactions

Kainic Acid results in decreased expression of SQSTM1 protein
NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

somatostatin

decreases expression

Kainic Acid results in decreased expression of SST mRNA

NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173

G

tachykinin, precursor 1

decreases expression

Kainic Acid results in decreased expression of TAC1 protein

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

TP53 induced glycolysis regulatory phosphatase

decreases expression
multiple interactions

Kainic Acid results in decreased expression of TIGAR protein
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]

NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029

G

toll-like receptor 4

multiple interactions
increases expression

perampanel inhibits the reaction [Kainic Acid results in increased expression of TLR4 protein]
Kainic Acid results in increased expression of TLR4 mRNA; Kainic Acid results in increased expression of TLR4 protein

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions
increases expression

Diazepam inhibits the reaction [Kainic Acid results in increased expression of TNF protein]; PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA]; TNF protein promotes the reaction [Kainic Acid results in increased uptake of Cobalt]
oridonin inhibits the reaction [Kainic Acid results in increased expression of TNF protein]
Kainic Acid results in increased expression of TNF mRNA; Kainic Acid results in increased expression of TNF protein

PMID:15869941 PMID:19700661 PMID:21589914 PMID:31430510 PMID:35544363

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

Kainic Acid results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thyrotropin releasing hormone

decreases expression
increases expression

Kainic Acid results in decreased expression of TRH mRNA
Kainic Acid results in increased expression of TRH mRNA

NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637

G

thyrotropin releasing hormone receptor

decreases expression

Kainic Acid results in decreased expression of TRHR protein

NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309

G

transmembrane immune signaling adaptor Tyrobp

increases expression

Kainic Acid results in increased expression of TYROBP mRNA

NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848

G

ubiquitin C-terminal hydrolase L1

increases expression

Kainic Acid results in increased expression of UCHL1 protein

NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590

G

U2AF homology motif kinase 1

decreases expression

Kainic Acid results in decreased expression of UHMK1 mRNA

NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292

G

URI1, prefoldin-like chaperone

increases expression

Kainic Acid results in increased expression of URI1 mRNA

NCBI chr 1:90,646,392...90,704,811
Ensembl chr 1:90,646,393...90,709,026

G

UTP3, small subunit processome component

decreases expression

Kainic Acid results in decreased expression of UTP3 mRNA

NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396

G

vesicle-associated membrane protein 7

decreases expression

Kainic Acid results in decreased expression of VAMP7 mRNA

NCBI chr12:16,728,486...16,764,261
Ensembl chr12:16,728,524...16,764,097

G

vascular endothelial growth factor A

decreases expression

Kainic Acid results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

wolframin ER transmembrane glycoprotein

increases expression

Kainic Acid results in increased expression of WFS1 mRNA

NCBI chr14:73,810,478...73,834,993
Ensembl chr14:73,810,404...73,835,602

G

XPA, DNA damage recognition and repair factor

increases expression

Kainic Acid results in increased expression of XPA mRNA

NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726

G

zinc finger CCHC-type containing 7

increases expression

Kainic Acid results in increased expression of ZCCHC7 mRNA

NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300

lincomycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

major histocompatibility complex, class I-related

affects expression

Lincomycin affects the expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

RT1 class Ia, locus A2

affects expression

Lincomycin affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19811
role	19818
biological role	19785
osmolyte	3447
compatible osmolytes	380
L-proline	298
L-proline derivative	274
(2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate	0
(2S,4R)-1-acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(benzothiazol-2-ylcarbonyl)butyl]-4-hydroxypyrrolidine-2-carboxamide	0
(3S,4S)-3,4-dihydroxy-L-proline	0
(5S)-5-(carboxymethyl)-L-proline	0
(R)-4-hydroxy-1-methyl-L-proline	0
1-[(2R)-2-amino-2-cyclohexylacetyl]-N-\{5-chloro-2-[2-(ethylamino)-2-oxoethoxy]benzyl\}-L-prolinamide	0
1-[3,3-dimethyl-2-(2-2-methylaminopropionylamino)butyryl]-4-phenoxypyrrolidine-2-[N-(1,2,3,4-tetrahydronaphthalen-1-yl)]carboxamide	0
1-\{[1-(2-amino-3-phenylpropionyl)pyrrolidine-2-carbonyl]amino\}-2-(3-cyanophenyl)ethaneboronic acid	0
3'-L-prolyl-AMP	0
3-hydroxy-L-proline +	0
4-O-(beta-L-Araf)-cis-L-Hyp	0
4-O-(beta-L-Araf-(1->2)-beta-L-Araf-(1->2)-beta-L-Araf)-cis-L-Hyp	0
4-hydroxy-L-proline +	0
4-oxo-L-proline	0
5-oxo-L-proline +	2
5-oxo-L-proline 2-naphthylamide	0
L-hydroxyproline 2-naphthylamide	0
L-prolinamide	0
L-proline 2-naphthylamide	0
N-(2,4-dinitrophenyl)-L-proline	0
N-Nitrosohydroxyproline	0
N-Nitrosoproline	0
N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide	0
N-acetyl-L-proline +	0
N-benzyloxycarbonyl-L-prolyl-L-prolinal	0
N-ethoxycarbonyl-D-phenylalanylprolyl-2-(4-aminobutyl)hydrazine	0
N-methylproline	0
XJB-5-131	0
[(R)-1-L-prolylpyrrolidin-2-yl]boronic acid	0
\{(2S,3S,4S)-2-carboxy-4-[(1Z,3E,5R)-5-carboxy-1-methylhexa-1,3-dienyl]pyrrolidin-3-yl\}acetic acid	0
aculene A	0
aculene B	0
alpha-Allokainic acid	0
beta-phenyl-D-phenylalanyl-N-(2,5-dichlorobenzyl)-L-prolinamide	0
captopril +	44
celesticetin	0
dainic acid A	0
domoic acid	8
fosinopril	23
fosinoprilat +	23
isodomoic acid A	0
kainic acid +	214
lincomycin +	6
methyl 1-methyl-5-oxo-L-prolinate	0
zofenopril	0
zofenoprilat	0
Path 2
Term	Annotations
CHEBI ontology	19811
subatomic particle	19809
composite particle	19809
hadron	19840
baryon	19809
nucleon	19809
atomic nucleus	19809
atom	19809
main group element atom	19759
main group molecular entity	19759
s-block molecular entity	19628
hydrogen molecular entity	19614
hydrides	19087
inorganic hydride	18091
pnictogen hydride	18080
nitrogen hydride	17987
azane	17796
ammonia	17795
organic amino compound	17795
amino acid	15943
alpha-amino acid	13846
L-alpha-amino acid	12846
glutamine family amino acid	10312
L-proline	298
L-proline derivative	274
(2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate	0
(2S,4R)-1-acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(benzothiazol-2-ylcarbonyl)butyl]-4-hydroxypyrrolidine-2-carboxamide	0
(3S,4S)-3,4-dihydroxy-L-proline	0
(5S)-5-(carboxymethyl)-L-proline	0
(R)-4-hydroxy-1-methyl-L-proline	0
1-[(2R)-2-amino-2-cyclohexylacetyl]-N-\{5-chloro-2-[2-(ethylamino)-2-oxoethoxy]benzyl\}-L-prolinamide	0
1-[3,3-dimethyl-2-(2-2-methylaminopropionylamino)butyryl]-4-phenoxypyrrolidine-2-[N-(1,2,3,4-tetrahydronaphthalen-1-yl)]carboxamide	0
1-\{[1-(2-amino-3-phenylpropionyl)pyrrolidine-2-carbonyl]amino\}-2-(3-cyanophenyl)ethaneboronic acid	0
3'-L-prolyl-AMP	0
3-hydroxy-L-proline +	0
4-O-(beta-L-Araf)-cis-L-Hyp	0
4-O-(beta-L-Araf-(1->2)-beta-L-Araf-(1->2)-beta-L-Araf)-cis-L-Hyp	0
4-hydroxy-L-proline +	0
4-oxo-L-proline	0
5-oxo-L-proline +	2
5-oxo-L-proline 2-naphthylamide	0
L-hydroxyproline 2-naphthylamide	0
L-prolinamide	0
L-proline 2-naphthylamide	0
N-(2,4-dinitrophenyl)-L-proline	0
N-Nitrosohydroxyproline	0
N-Nitrosoproline	0
N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide	0
N-acetyl-L-proline +	0
N-benzyloxycarbonyl-L-prolyl-L-prolinal	0
N-ethoxycarbonyl-D-phenylalanylprolyl-2-(4-aminobutyl)hydrazine	0
N-methylproline	0
XJB-5-131	0
[(R)-1-L-prolylpyrrolidin-2-yl]boronic acid	0
\{(2S,3S,4S)-2-carboxy-4-[(1Z,3E,5R)-5-carboxy-1-methylhexa-1,3-dienyl]pyrrolidin-3-yl\}acetic acid	0
aculene A	0
aculene B	0
alpha-Allokainic acid	0
beta-phenyl-D-phenylalanyl-N-(2,5-dichlorobenzyl)-L-prolinamide	0
captopril +	44
celesticetin	0
dainic acid A	0
domoic acid	8
fosinopril	23
fosinoprilat +	23
isodomoic acid A	0
kainic acid +	214
lincomycin +	6
methyl 1-methyl-5-oxo-L-prolinate	0
zofenopril	0
zofenoprilat	0

paths to the root